Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefan Willmann

Showing results (61-70 of 80) with videos related to

Pageof 8
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|July 6, 2019
Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic SamplingAlexander Solms, Matthias Frede, Scott D Berkowitz, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 6, 2022
Model-informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart diseaseStefan Willmann, Ibrahim Ince, Maurice Ahsman, et al.
Frontiers in Physiology|January 29, 2013
Development of a physiologically based computational kidney model to describe the renal excretion of hydrophilic agents in ratsChristoph Niederalt, Thomas Wendl, Lars Kuepfer, et al.
Journal of Clinical Pharmacology|June 29, 2021
Predictive Performance of Physiology-Based Pharmacokinetic Dose Estimates for Pediatric Trials: Evaluation With 10 Bayer Small-Molecule Compounds in ChildrenIbrahim Ince, André Dallmann, Sebastian Frechen, et al.
Journal of Thrombosis and Thrombolysis|April 24, 2020
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolismAlexander Solms, Stefan Willmann, Isabel Reinecke, et al.
Journal of Thrombosis and Thrombolysis|April 24, 2020
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolismIsabel Reinecke, Alexander Solms, Stefan Willmann, et al.
Journal of Thrombosis and Thrombolysis|April 24, 2020
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillationLiping Zhang, Xiaoyu Yan, Keith A A Fox, et al.
Thrombosis Journal|December 12, 2018
Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I studyDagmar Kubitza, Stefan Willmann, Michael Becka, et al.
Therapeutic Advances in Cardiovascular Disease|August 1, 2019
Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndromeLiping Zhang, Xiaoyu Yan, Partha Nandy, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 22, 2021
Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically-based pharmacokinetic predictionsStefan Willmann, Katrin Coboeken, Yang Zhang, et al.
Pageof 8

Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
CPT: Pharmacometrics & Systems Pharmacology|July 6, 2019
Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic SamplingAlexander Solms, Matthias Frede, Scott D Berkowitz, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 6, 2022
Model-informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart diseaseStefan Willmann, Ibrahim Ince, Maurice Ahsman, et al.
Frontiers in Physiology|January 29, 2013
Development of a physiologically based computational kidney model to describe the renal excretion of hydrophilic agents in ratsChristoph Niederalt, Thomas Wendl, Lars Kuepfer, et al.
Journal of Clinical Pharmacology|June 29, 2021
Predictive Performance of Physiology-Based Pharmacokinetic Dose Estimates for Pediatric Trials: Evaluation With 10 Bayer Small-Molecule Compounds in ChildrenIbrahim Ince, André Dallmann, Sebastian Frechen, et al.
Journal of Thrombosis and Thrombolysis|April 24, 2020
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolismAlexander Solms, Stefan Willmann, Isabel Reinecke, et al.
Journal of Thrombosis and Thrombolysis|April 24, 2020
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolismIsabel Reinecke, Alexander Solms, Stefan Willmann, et al.
Journal of Thrombosis and Thrombolysis|April 24, 2020
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillationLiping Zhang, Xiaoyu Yan, Keith A A Fox, et al.
Thrombosis Journal|December 12, 2018
Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I studyDagmar Kubitza, Stefan Willmann, Michael Becka, et al.
Therapeutic Advances in Cardiovascular Disease|August 1, 2019
Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndromeLiping Zhang, Xiaoyu Yan, Partha Nandy, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 22, 2021
Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically-based pharmacokinetic predictionsStefan Willmann, Katrin Coboeken, Yang Zhang, et al.
Pageof 8